ST.
PAUL, Minn., Jan. 21,
2025 /PRNewswire/ -- ScaleReady, in collaboration
with Wilson Wolf Manufacturing, Bio-Techne Corporation and
CellReady, today announced that BrainChild Bio has been awarded a
$300,000 G-Rex® Grant. The G-Rex®
Grant will support expeditious process development and commercial
readiness of BCB-276, BrainChild Bio's lead autologous CAR-T
therapy for the treatment of diffuse intrinsic pontine glioma
(DIPG), an incurable type of pediatric brain tumor. BrainChild Bio
plans to advance BCB-276 into a multi-center Phase 2 pivotal
clinical trial in 2025 for the treatment of children and young
adults with DIPG.
"G-Rex has been an essential element of our clinical CAR-T
manufacturing program at Seattle Children's dating back to 2012. We
greatly appreciate the support of ScaleReady's G-Rex Grant Program
as well as the technical expertise offered to us by ScaleReady
related to new advancements," said Dr. Michael Jensen, Chief Scientific Officer at
BrainChild Bio.
"We have a tremendous amount of respect for pioneering CAR-T
therapies that Dr. Jensen and his team have advanced over the last
15 years. Their relentless pursuit of cancer cures is inspiring.
It's an honor for our team to be able to help accelerate
BrainChild's novel BCB-276 treatment for brain tumors to those in
need and this program is perfectly aligned with our goal of
bringing hope to cancer patients," said John Wilson, CEO of Wilson Wolf Manufacturing
Corporation and co-inventor of G-Rex.
As part of the G-Rex Grant, BrainChild Bio will perform
process development and optimization of their G-Rex based CAR-T
cell manufacturing process in anticipation of a pivotal clinical
trial. Through this G-Rex Grant, ScaleReady will help BrainChild
quickly establish optimal process simplicity, consistency, and
flexibility in their manufacturing approach for BCB-276.
Additionally, BrainChild Bio will have the option to evaluate
CellReady's standardized CAR-T cell process, a highly efficient
7-day manufacturing process. The CellReady CAR-T process is a fully
closed end-to-end process that incorporates the use of closed
system G-Rex bioreactors and Bio-Techne's new closed system ProPak
GMP cytokines in a manufacturing workflow capable of delivering
high-throughput products to patients.
ScaleReady's G-Rex Grant Program is a $20M initiative to advance the state of cell and
gene-modified cell therapy (CGT) development and manufacturing by
awarding individual Grant Awards worth up to $300,000. G-Rex Grant Recipients also gain access
to exclusive support from ScaleReady's growing consortium of G-Rex
Grant Partners who bring best-in-class tools and technologies as
well as unparalleled knowledge and expertise in the areas of cGMP
manufacturing, quality and regulatory affairs, CGT business
operations, and more.
For more information about the G-Rex® Grant Program, please
contact info@scaleready.com.
About ScaleReady
ScaleReady provides the field of cell
and gene-modified cell therapy (CGT) with a G-Rex centric
manufacturing platform that enables the world's most practical,
flexible, scalable, and affordable CGT drug product development and
manufacturing.
The G-Rex manufacturing platform is currently used by a rapidly
growing list of over 800 organizations and is producing drug
products for approximately 50% of CGT clinical trials as well as 5
commercially approved CGT drugs.
CGT entities relying on the breadth and scope of ScaleReady's
expertise can expect to save years of time and millions of dollars
on the path to CGT commercialization.
For more information about the ScaleReady G-Rex® Grant Program,
please contact info@scaleready.com.
About Wilson Wolf Manufacturing
Wilson Wolf (www.wilsonwolf.com) is dedicated to
simplifying cell and gene-modified cell (CGT) therapy research,
process development, and manufacturing. This is being accomplished
through its scalable G-Rex technology, which is used throughout the
world in CGT applications ranging from basic research to commercial
drug production.
Wilson Wolf's mission is to
create hope for cancer patients, one G-Rex® device at a time.
About Bio-Techne Corporation
Bio-Techne Corporation
(NASDAQ: TECH) is a global life sciences company providing
innovative tools and bioactive reagents for the research and
clinical diagnostic communities. Bio-Techne, in partnership with
Wilson Wolf, is creating products
such as media and cytokines that are specifically tailored to
G-Rex® Bioreactors, including right-sized reagent quantities in
containers that are tailored to high throughput closed-system
manufacturing. For more information on Bio-Techne and its brands,
please visit https://www.bio-techne.com or follow the Company on
social media at: Facebook, LinkedIn, Twitter or YouTube.
Contact: David Clair, Vice
President, Investor Relations & Corporate Development
david.clair@bio-techne.com
612-656-4416
About CellReady LLC
CellReady is the world's first and
only G-Rex centric contract development and manufacturing
organization (CDMO) specializing in G-Rex based cell and
gene-modified cell therapy development and manufacturing. The
company offers a wide range of services to support the development
and commercialization of these therapies.
CellReady's mission is to create hope for cancer patients, one
G-Rex® process at a time.
About BrainChild Bio
BrainChild Bio, Inc., is a
kids-first, clinical-stage biotechnology company harnessing the
power of CAR T-cell technology to treat tumors in the central
nervous system, prioritizing pediatric indications with plans to
expand into adult CNS tumors, specifically Glioblastoma and Brain
Metastasis. BrainChild Bio is advancing a next-generation CAR
T-cell therapy platform for tumors of the CNS that weaves together
synthetic technologies, including multiplex targeting and enhanced
potency controls, to enable multiple targets in a single CAR T-cell
therapy, novel transgenes to increase potency, delivery technology
for durable efficacy, and streamlined CAR T-cell design and
manufacturing. BrainChild Bio's lead drug candidate is BCB-276, an
autologous CAR T-cell therapy that targets the immune checkpoint
B7-H3, that is advancing in clinical trials for the treatment of
diffuse intrinsic pontine glioma (DIPG), a pediatric cancer that
forms in the brainstem which currently has no approved treatments.
More information is available at www.brainchildbio.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/scaleready-announces-a-g-rex-grant-has-been-awarded-to-brainchild-bio-302355642.html
SOURCE Bio-Techne Corporation